Please login to the form below

Not currently logged in
Email:
Password:

companion diagnostic

This page shows the latest companion diagnostic news and features for those working in and with pharma, biotech and healthcare.

Merck gets first approval for MET inhibitor tepotinib in Japan

Merck gets first approval for MET inhibitor tepotinib in Japan

The approval comes on the back of a phase 2 study – called VISION – which enrolled patients with METex14-positive NSCLC based on a just-approved companion diagnostic developed by genome analysis

Latest news

More from news
Approximately 1 fully matching, plus 61 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    The response has been a surge of interest in developing novel companion biomarkers, and biomarkers that allow personalisation of therapy. ... The confounding issue is that, in the case of PD-1/PD-L1 drugs, each developer uses its own companion diagnostic

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    At the moment there is no companion diagnostic for NTRK fusions so patients need to be identified through genomic profiling techniques such as immunohistochemistry or genetic sequencing approaches, which tend to

  • Harnessing complexity Harnessing complexity

    This delicate balance between companion diagnostics' clinical utility and their potential confounding impact on patient treatment is a growing dilemma. ... Answering this question in full requires a scientific journey to better understand what a

  • Diagnostics are rising up the pharma value chain Diagnostics are rising up the pharma value chain

    Diagnostic drivers. It's not just this idea of changing public attitudes that is creating renewed interest in the diagnostics sector; the sector is also influenced by the wider forces affecting ... GlaxoSmithKline and Boehringer Ingelheim have had

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    50. NanoString Technologies/ Celgene. Development. Development of a companion diagnostic assay.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Mastering the precision medicine opportunity

    Novartis and Roche are two champions of personalised medicine, shaping the area with the launch of targeted treatments combined with a companion diagnostic to support patient identification. ... approval of their new  FoundationOne CDx, the first and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics